Objective: To investigate the clinical values of luteinizing hormone-releasing hormone (LHRH) α (triptorelin) stimulating test in the differential diagnoses of hypothalamus-pituitary-gonad axis (HPGA) disorders.
Methods: A total of 229 male patients with various HPGA disorders were recruited for triptorelin stimulating test. And all patients were followed up for 12 - 48 months until a definite diagnosis was made. The values of triptorelin stimulating test in the differential diagnoses of HPGA disorders were assessed by examining the close relationship between LHmax and the final clinical diagnosis.
Results: (1) LH levels rose steady after an intramuscular injection of triptorelin 100 µg and the time of LHmax appeared at 45 - 60 min. (2) LHmax < 4 U/L indicated the function of HPGA was not activated. LHmax in the range of 4 - 12 U/L indicated the patients might have constitutional delayed puberty development. LHmax > 12 U/L indicated the fulfilled puberty development.
Conclusion: Triptorelin stimulating test can precisely evaluate the functions of HPGA in various HPGA disorders and provide valuable information for the differential diagnoses in constitutional delayed puberty development, hypogonadotropic hypogonadism, central and peripheral precocious puberty disorders.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Adult height in girls with idiopathic central precocious puberty treated with triptorelin.
Front Endocrinol (Lausanne)
December 2024
Department of Pediatrics, Hospital Niño Jesús, Universidad Autónoma de Madrid, Madrid, Spain.
Objective: Idiopathic central precocious puberty (CPP) precipitates epiphyseal fusion of growth plates in long bones, leading to reduced adult stature. Gonadotropin-releasing hormone analogues (GnRHa) are the treatment of choice for idiopathic CPP, but their benefit on height gain is unclear. We aimed to elucidate the effects of GnRHa treatment on adult height in girls with idiopathic CPP.
View Article and Find Full Text PDFA Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty.
Adv Ther
December 2024
Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei,, China.
Article Synopsis
- - This phase 3 study evaluated a 6-month prolonged release formulation of triptorelin for treating central precocious puberty (CPP) in Chinese children, focusing on its efficacy, safety, and pharmacokinetics.
- - In an open-label trial involving 66 children (93.9% girls), the treatment successfully suppressed luteinizing hormone (LH) levels in all participants by month 6, with 98.5% maintaining this suppression at month 12, alongside other positive hormone and development outcomes.
- - The study found that triptorelin had a safety profile similar to previous studies in non-Chinese children, with limited adverse events reported, reinforcing its effectiveness and safety in managing CPP.
Revising LH cut-off for the diagnosis of central precocious puberty via triptorelin stimulation assay.
Endocrine
October 2024
Pediatric Division, Department of Pediatrics, University Hospital of Verona, Verona, Italy.
Article Synopsis
- Precocious puberty (PP) in girls is characterized by breast development before age 8, with a diagnostic procedure using GnRH stimulation to measure LH levels, traditionally with a cutoff of 15 IU/L, but many still showed lower levels.
- The study aimed to establish a new lower LH threshold of 5 IU/L for earlier diagnosis of central precocious puberty (CPP) and assess other diagnostic parameters.
- Results indicated that girls with higher LH levels and other indicators, like growth velocity, were more likely to have axis activation, leading to the new proposed LH threshold for better diagnostic accuracy.
Central Precocious Puberty in a Male Child With Down Syndrome: A Case Report.
Cureus
August 2024
Department of Pediatrics, College of Medicine, King Faisal University, Al-Ahsa, SAU.
Gonadal dysfunction is a well-known endocrine manifestation of Down syndrome (DS) in men. Herein, we report a case of a seven-year-old boy with DS who developed precocious puberty, presenting with a six-month history of frequent erections, sudden growth spurts, and adult odors. Clinical examination revealed stage 2 puberty, with pubic hair development at stage 2 based on Tanner staging and bilateral testicular volumes of 6 mm.
View Article and Find Full Text PDFUse of a slow-release GnRH implant in an adult billy goat.
Tierarztl Prax Ausg G Grosstiere Nutztiere
August 2024
Veterinary Clinic for Reproductive Medicine and Neonatology, Justus-Liebig-University Giessen, Germany.
Article Synopsis
- A special implant called deslorelin was put into a healthy male goat to see if it could make him temporarily infertile and reduce his sexual behavior.
- After 6 weeks, the goat's testicles didn't change in size, and there were no effects on his hormone levels.
- The goat's ability to produce sperm also stayed normal, showing that this implant didn't affect his fertility.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!